EcoDrugPlus

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSGACG00000016696
Gene Symbol: CYP3A65
1 Cross references
494 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSGACG00000016687
Gene Symbol: CYP3A65
1 Cross references
572 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSGACG00000016669
Gene Symbol: CYP3A65
1 Cross references
572 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily C, Polypeptide 3

Ensembl ID : ENSGACG00000010952
Gene Symbol: CYP3C3
1 Cross references
560 Possible Orthologues:

Cytochrome P450, Family 46, Subfamily A, Polypeptide 1, Tandem Duplicate 4

Ensembl ID : ENSGACG00000005410
Gene Symbol: CYP46A1.4
1 Cross references
259 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1a

Ensembl ID : ENSGACG00000004051
Gene Symbol: DGAT1A
1 Cross references
192 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1b

Ensembl ID : ENSGACG00000008951
Gene Symbol: DGAT1B
1 Cross references
188 Possible Orthologues:

Dihydroorotate Dehydrogenase

Ensembl ID : ENSGACG00000015466
Gene Symbol: DHODH
1 Cross references
173 Possible Orthologues:

Dihydropyrimidine Dehydrogenase B

Ensembl ID : ENSGACG00000014875
Gene Symbol: DPYDB
1 Cross references
217 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSGACG00000014457
Gene Symbol: DDR2
1 Cross references
205 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSGACG00000016132
Gene Symbol: DDR2
1 Cross references
189 Possible Orthologues:

Dopamine Receptor D1

Ensembl ID : ENSGACG00000018420
Gene Symbol: DRD1
2 Cross references
188 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).